{"id":11709,"date":"2024-05-20T08:23:00","date_gmt":"2024-05-20T08:23:00","guid":{"rendered":"https:\/\/distilinfo.com\/healthplan\/?p=11709"},"modified":"2024-05-20T08:30:19","modified_gmt":"2024-05-20T08:30:19","slug":"boehringer-partners-cigna-to-biosimilar","status":"publish","type":"post","link":"https:\/\/distilinfo.com\/healthplan\/boehringer-partners-cigna-to-biosimilar\/","title":{"rendered":"Boehringer Partners with Cigna to Boost Humira Biosimilar | A Strategic Overview"},"content":{"rendered":"

Table of Contents<\/h2>\n
    \n
  1. Introduction to Biosimilars<\/li>\n
  2. Overview of Boehringer’s Strategy<\/li>\n
  3. Details of the Partnership with Cigna<\/li>\n
  4. Market Implications<\/li>\n
  5. Patient Impact and Access<\/li>\n
  6. FAQs<\/li>\n
  7. Conclusion<\/li>\n<\/ol>\n

    Introduction to Biosimilars<\/a><\/h3>\n

    Biosimilars<\/a> are officially approved versions of original “innovator” drugs that have lost patent protection, designed to be similar in terms of safety, effectiveness, and active ingredients. Due to its widespread use in treating chronic inflammatory diseases, Adalimumab, the active ingredient in Humira, has several biosimilars.<\/p>\n

    Boehringer Ingelheim, a key player in the pharmaceutical industry, has recently partnered with Cigna’s subsidiary<\/a> Quallent Pharmaceuticals to enhance the distribution and accessibility of its Humira biosimilar. This collaboration comes after a slow initial launch and aims to challenge the dominance of AbbVie’s Humira, the original version of the drug. This article explores the significance of this partnership, its impact on the market, and the broader implications for patients and healthcare providers.<\/p>\n

    Overview of Boehringer’s<\/a> Strategy<\/h3>\n

    Boehringer Ingelheim<\/a> initially launched its Humira biosimilar under the brand name Cyltezo, and later an unbranded version. Despite offering these at significant discounts\u20145% and 81% respectively\u2014the uptake was slower than anticipated. This led to a strategic pivot towards a hybrid marketing model and, eventually, the partnership with Quallent Pharmaceuticals.<\/p>\n

    Details of the Partnership with Cigna<\/h3>\n

    Under the new agreement, Boehringer will supply Quallent Pharmaceuticals with a citrate-free adalimumab-adbm, which promises to increase patient comfort during administration. Quallent, in turn, will handle the distribution, significantly broadening the reach of Boehringer’s biosimilars through Cigna’s extensive network.<\/p>\n

    Market Implications<\/h3>\n

    This partnership is poised to disrupt the market by providing more affordable biosimilar options. Cigna CEO David Cordani has stated that these biosimilars will be priced at approximately 85% lower than Humira, making them significantly more accessible. Following a similar arrangement with Alvotech, the deal with Boehringer places Quallent in a strong position to supply both high- and low-concentration biosimilar versions.<\/p>\n

    Patient Impact and Access<\/h3>\n

    The agreement is expected to enhance access to biosimilars for patients suffering from chronic inflammatory diseases by lowering costs and expanding availability. This could lead to increased competition and further reductions in the price of these critical medications.<\/p>\n

    FAQs<\/h3>\n

    Q1: What is a biosimilar?
    \nA biosimilar is a biologic medical product similar to another already approved biological medicine. Biosimilars are approved according to the same standards of pharmaceutical quality, safety, and efficacy that apply to all biological medicines.<\/p>\n

    Q2: How does the partnership between Boehringer and Cigna benefit patients?
    \nThe partnership aims to make biosimilars more accessible and affordable, particularly for patients with chronic conditions who require ongoing treatment.<\/p>\n

    Q3: Will the biosimilars be available immediately?
    \nThe biosimilars are expected to be rolled out progressively as the companies work through regulatory and marketing strategies to ensure broad access.<\/p>\n

    Conclusion<\/h3>\n

    The strategic partnership between Boehringer Ingelheim and Quallent Pharmaceuticals represents a significant development in the pharmaceutical industry. By making biosimilars more accessible and affordable, this collaboration not only challenges the existing market dominance of Humira but also provides patients with more options in their healthcare treatments, potentially improving the quality of life for many.<\/p>\n","protected":false},"excerpt":{"rendered":"

    Table of Contents Introduction to Biosimilars Overview of Boehringer’s Strategy Details of the Partnership with Cigna Market Implications Patient Impact… Continue Reading <\/i><\/a><\/p>\n","protected":false},"author":1,"featured_media":11713,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_genesis_hide_title":false,"_genesis_hide_breadcrumbs":false,"_genesis_hide_singular_image":false,"_genesis_hide_footer_widgets":false,"_genesis_custom_body_class":"","_genesis_custom_post_class":"","_genesis_layout":"","footnotes":""},"categories":[1],"tags":[346],"_links":{"self":[{"href":"https:\/\/distilinfo.com\/healthplan\/wp-json\/wp\/v2\/posts\/11709"}],"collection":[{"href":"https:\/\/distilinfo.com\/healthplan\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/distilinfo.com\/healthplan\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/distilinfo.com\/healthplan\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/distilinfo.com\/healthplan\/wp-json\/wp\/v2\/comments?post=11709"}],"version-history":[{"count":3,"href":"https:\/\/distilinfo.com\/healthplan\/wp-json\/wp\/v2\/posts\/11709\/revisions"}],"predecessor-version":[{"id":11718,"href":"https:\/\/distilinfo.com\/healthplan\/wp-json\/wp\/v2\/posts\/11709\/revisions\/11718"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/distilinfo.com\/healthplan\/wp-json\/wp\/v2\/media\/11713"}],"wp:attachment":[{"href":"https:\/\/distilinfo.com\/healthplan\/wp-json\/wp\/v2\/media?parent=11709"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/distilinfo.com\/healthplan\/wp-json\/wp\/v2\/categories?post=11709"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/distilinfo.com\/healthplan\/wp-json\/wp\/v2\/tags?post=11709"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}